Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Investor Presentation (October 2025)
31 slides from Anteris Technologies Global's investor presentation, October 2025
Slide 1: October 2025
October 2025 NASDAQ: AVR | ASX: AVR
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Anteris Technologies Global Corp. (“Anteris,” the “Company,” “we” or “us” or "our"). This presentation, and its contents and the accompanying discussion with management are confidential and may not be further copied, distributed or passed on, directl
Slide 3: 3
3
Slide 4: Anteris Technologies – Executing on strategy
Anteris Technologies – Executing on strategy Building commercial readiness for a new class of TAVR that mimics a healthy aortic valve 1 Successfully priced U.S. IPO and listed on Nasdaq in December 2024 - Enhancing liquidity and visibility in the world’s largest healthcare investment market 2 Total
Slide 5: Investment Highlights
Investment Highlights The only biomimetic balloon expandable TAVR with 130 treated patients Poised to disrupt a high value, growth Path to Commercialization market Proprietary, Multi-billion-dollar Clinical Commercial Commercial First-in-Class TAVR global TAVR market Validation Readiness Launch 130
Slide 6: Highly Experienced Leadership – Clinical, Operational, Commercial
Highly Experienced Leadership – Clinical, Operational, Commercial Wayne Paterson David St Denis Matthew McDonnell Dr. Chris Meduri VICE CHAIRMAN & CEO PRESIDENT & DIRECTOR CHIEF FINANCIAL OFFICER CHIEF MEDICAL OFFICER Mr. Paterson has served as CEO since March 2017 and was appointed Vice Mr. St Deni
Slide 7: Board of Directors
Board of Directors John Seaberg Wayne Paterson Stephen Denaro Dave Roberts Greg Moss David St Denis CHAIRMAN VICE CHAIRMAN & CEO DIRECTOR & COMPANY SECRETARY NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR PRESIDENT & DIRECTOR Mr. Seaberg has been Mr. Paterson has served as CEO Mr. Denaro has been a d
Slide 8: Global Manufacturing Footprint
Global Manufacturing Footprint Purpose-built infrastructure designed for efficient scale-up and commercial readiness 8
Slide 9: TAVR market opportunity expected to reach US$9.9bn in 2028
TAVR market opportunity expected to reach US$9.9bn in 2028 Underpenetrated patient population with only 15-20%1 of severe aortic stenosis cases treated today TAVR Aortic Stenosis & Valve-in-Valve Market2 Potential for further significant growth 14.0 Currently 3 industry trials in progress, anticipat
Slide 10: A New Class of TAVR
A New Class of TAVR
Slide 11: Aortic Stenosis (AS) - Current Treatment Options
Aortic Stenosis (AS) - Current Treatment Options SAVR – Invasive, open-heart surgery A life-threatening condition caused by narrowing of the aortic valve Patients with severe AS have a 50% risk of dying within 2 Years1 TAVR - Minimally invasive procedure 1. Leon MB, Smith CR, Mack M, et al. Transcat
Slide 12: Yesterday’s TAVRs were not developed for today’s patients
Yesterday’s TAVRs were not developed for today’s patients DurAVR® was deliberately designed for younger and more active patients Patients need a safer alternative to Patients need a valve that restores an active open heart surgery lifestyle for the rest of their life First & second Third generation
Slide 13: Anteris set out to address the needs in TAVR by asking different questions
Anteris set out to address the needs in TAVR by asking different questions How does a healthy How can we mimic a How can we put that How do we deliver aortic valve perform? native valve? valve in a frame? the valve? Our expert panel of physicians advised the Company what they wanted in a next genera
Slide 14: DurAVR®: A New Class of TAVR
DurAVR®: A New Class of TAVR Single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve. 14
Slide 15: DurAVR® Sustained hemodynamic performance to year
DurAVR® Sustained hemodynamic performance to 1 year Mean Annular Diameter: 22.4 mm MPG (Mean Pressure Gradient mmHg) 8.6 EOA (Effective Orifice Area cm2) 2.1 DVI (Doppler Velocity Index) 0.58 Mean Pressure Gradient (MPG) • The average pressure across the aortic valve between the left ventricle and a
Slide 16: A balloon expandable valve with self-expanding hemodynamics is like the holy grail
“ A balloon expandable valve with self-expanding hemodynamics is like the “ holy grail. Dr Michael Reardon Professor of Cardiothoracic Surgery, Allison Family Distinguished Chair of Cardiovascular Research Methodist DeBakey Heart & Vascular Center Clinician panel discussion, PCR London Valves 2023.
Slide 17: Restores flow dynamics, significantly reducing left ventricular (LV) mass
Restores flow dynamics, significantly reducing left ventricular (LV) mass SEVERE AORTIC STENOSIS Increased LV mass is an adaptive response to the increased workload caused by the narrowed aortic valve. Untreated it may progress to heart failure. A narrowed aortic valve creates increased pressure in
Slide 18: DurAVR® is the first aortic valve to restore normal aortic flow
DurAVR® is the first aortic valve to restore normal aortic flow Normal Aortic Flow Impaired Aortic Flow When compared to a healthy aortic valve, DurAVR® THV Normal Valve (n=5) vs: TAVR (n=4) p<0.05 | SAVR (n=8) p<0.01 showed no significant difference in flow (p>0.05) Healthy Aortic Valve Severe AS S
Slide 19: Valve in Valve (ViV) expanding TAVR market
Valve in Valve (ViV) expanding TAVR market – US$2.5bn by 2028 Existing bioprosthetic valves fail and patients need retreatment ViV Challenges Preserving coronary access, providing good hemodynamic result Solution – DurAVR® THV Short-frame valve, paradigm-shifting hemodynamic performance and large op
Slide 20: Path to Commercialization
Path to Commercialization
Slide 21: 130 DurAVR® patients – support pivotal trial launch (PARADIGM Trial)
130 DurAVR® patients – support pivotal trial launch (PARADIGM Trial) 49 patients treated YTD (2025) 2021 2022 2023 2024 2025 First-in-human (“Embark”) Study FPI Nov 2021 FDA submission Early Feasibility Study (“EFS”) - DurAVR® FDA approval Ongoing monitoring Valve-in-Valve Compassionate use Patient
Slide 22: PARADIGM Trial
PARADIGM TRIAL
Slide 23: The first all-risk, head-to-head TAVR registration trial
The first all-risk, head-to-head TAVR registration trial “All Comers” Randomized Cohort 1-year data used to support PMA Submission Assessment for Eligibility Enrollment I Study Co-Chairs: Dr. Michael J. Reardon, Professor Stephan Windecker 1:1 Randomization (All surgical risk strata) Clinical Trial
Slide 24: PARADIGM Trial – Planned enrollment and revenue
PARADIGM Trial – Planned enrollment and revenue* Category B Medicare coverage of US$25k per device* ENROLLMENT FOLLOW UP REVIEW Patients screened for eligibility. Patients followed up at 1 month, The 1-year data is included in a PMA If selected, they are randomized and 1 year (primary study applicat
Slide 25: Supplementary studies not expected to be required for all-risk TAVR approval
Supplementary studies not expected to be required for all-risk TAVR approval* “Low Risk” Randomized Continued Access Valve-in-Valve Cohort Commences when ‘all-risk’ PMA study recruitment concludes Standalone parallel registry Assessment for Eligibility Enrollment II Enrollment Assessment for Eligibi
Slide 26: Anticipated Milestones
Anticipated Milestones Q4 2024 (completed) Q2 2025 (completed) Q4 2025 Q2 2026 Q4 2026 • Targeted DurAVR® IDE approval for • US IPO & NASDAQ LISTING • PARADIGM - EU Investigator Meeting • DurAVR® CE Mark Submission • PARADIGM PARADIGM Trial* • TCT presentation: Flow • PCR – Innovation session • PCR
Slide 27: Key Takeaways
Key Takeaways Building commercial readiness for a new class of TAVR that mimics a healthy aortic valve 1 DurAVR® THV - Proprietary, new class of TAVR for aortic stenosis - Easy, predictable balloon expandable deployment with the function of a healthy, native aortic valve 2 US$9.9bn global TAVR marke
Slide 28: Appendices
Appendices
Slide 29: Medical Advisory Board
Medical Advisory Board Anteris is guided by a global team of well-regarded cardiovascular Physician advisors North America Europe Australia 29
Slide 30: Procedural Success Endpoints Across Various Anatomies
Procedural Success Endpoints Across Various Anatomies Technical Success (VARC 3): 94% Challenging anatomies treated Device Success (VARC 3): 92.3% (Baseline MDCT) n = 65 Severe annular calcium Extreme leaflet calcium Type 1 bicuspid Extreme LVOT calcium 1 patient required 2 valves; 3 patients had va
Slide 31: DurAVR® Data Spotlight
DurAVR® Data Spotlight Zero Prosthesis Patient Mismatch Low Paravalvular Leak (PPM) in Small Annuli Measured at 1-year, n=37 No moderate or severe PVL 1. Puri R. DurAVR®: A Novel First-in-Class Biomimetic Transcatheter Aortic Valve 1-Year Performance. Oral Presentation at: Sydney Valves; March 2025;
Anteris Technologies Global — Investor Presentation (October 2025) on 6ix